Sentinel Lymph Node Biopsy after Neoadjuvant Treatment for Breast Cancer. The Validation Protocol

Bordea, C; Gherghe, Mirela; Capsa, Cristina; Noditi, Aniela; Ianovici, Ciprian; Caragheorghe, George; Blidaru, Alexandru

doi:10.21614/chirurgia.116.2.178

Cited by 2 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, they reiterated that the lowest detection rate for a SLN mapping method was for the use of BD alone, with the pooled IR for this technique being 86.8% [ 50 ]. In the research groups included in our review that only performed SLN mapping through radioisotopic method, the IR varied between 80.8%, obtained by Pecha et al [ 33 ], and 97.8%, attained by Bordea et al [ 26 ], which is once again in concordance with our results.…”

Section: Discussionsupporting

confidence: 92%

“…In their prospective study, Bordea et al [ 26 ] aimed to evaluate the accuracy of SLNB after NAC and identify clinical and pathological factors that correlated with SLN invasion. The analysis included 47 consecutive breast cancer patients at stages II B-III A who underwent NAC and achieved a complete axillary response.…”

Section: Resultsmentioning

confidence: 99%

“…The inclusion criteria were met by 20 papers, which were finally included in this qualitative review. Most researcher groups (n = 11) used a combination of 99m Tc-labelled radioisotopes and BD for their SLN mapping [ 24 , 28 , 29 , 30 , 31 , 32 , 37 , 38 , 39 , 40 , 41 ], while nine studies performed SLN identification through radioisotopic mapping alone [ 9 , 18 , 26 , 33 , 34 , 35 , 36 , 42 ]. In all papers, SLNB was followed by ALND to ensure the accurate assessment of the axilla.…”

Section: Resultsmentioning

confidence: 99%

“…The nodes with the highest uptake were excised and sent for histopathological examination. Following that step, it underwent analysis using paraffin-embedded sections and immunohistochemistry techniques for a precise diagnosis [ 26 ].…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Axillary Conversion after Neoadjuvant Chemotherapy—A Single-Tertiary Centre Experience and Review of the Literature

Lazar,

Mutuleanu,

Spiridon

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

(1) Introduction: Sentinel lymph node biopsy (SLNB) is widely used in breast cancer patients who undergo neoadjuvant chemotherapy (NAC), replacing axillary lymph node dissection. While commonly accepted for cN0 patients, its role in cN1/2 patients remains controversial. Our study aims to investigate the role of SLNB in BC patients who underwent prior NAC and compare our results to those of other studies presented in the literature. (2) Materials and methods: Our retrospective study included 102 breast cancer patients who received NAC before 99mTc-albumin Nanocolloid SLN mapping and SLNB was performed, completed or not with axillary dissection. A review based on the PRISMA statement was also carried out, encompassing 20 studies. (3) Results: The lymphoscintigraphy performed after the administration of NAC presented an identification rate (IR) of 93.13%. IR for SLNB was 94.11%, with a false-negative rate (FNR) of 7.4%. After a median follow-up of 31.3 months, we obtained a distant disease-free survival rate of 98%. The results obtained by other groups were similar to those of our study, presenting IR in the range 80.8–96.8%, with FNR varying from 0 to 22%. (4) Conclusions: on conclusion, SLNB can accurately determine the lymph node status, with an acceptable FNR and maintain its expected prognostic role with low recurrence rates, and our results are comparable to those obtained by other studies.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Axillary Conversion after Neoadjuvant Chemotherapy—A Single-Tertiary Centre Experience and Review of the Literature

Lazar,

Mutuleanu,

Spiridon

et al. 2023

Diagnostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…If this is not possible, they recommend a baseline PET-CT or CT scan before vaccination. Other imagistic methods for lymph node staging, lymphoscintigraphy for example, may also be influenced by vaccination [ 28 , 29 , 30 , 31 ]. This comes in addition to the Society of Breast Imaging (SBI)’s recommendations, from Canada [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

Understanding COVID Vaccination and Its Implication in Cancer Patients’ Imaging of Lymph Nodes by PET-CT

et al. 2022

Self Cite

View full text Add to dashboard Cite

(1) Background: The appearance of enlarged lymph nodes on imaging adds another layer of complexity to the differential diagnosis of disease progression versus immune response to COVID-19 vaccines. Our aim was to find an optimal timing between the vaccination and the PET-CT scan. (2) Methods: 25 cancer patients with 18F-FDG PET-CT evaluations and a history of COVID-19 vaccination between September 2021 and December 2021 were retrospectively analyzed to characterize the lymph nodes related to the time interval from COVID vaccination. (3) Results: All patients presented one or more adenopathies localized in the ipsilateral axilla (96%), ipsilateral cervical area (20%), ipsilateral retropectoral (20%) and pulmonary hilum (8%). The median value of SUVmax was 3.5 ± 0.5. There was a significant indirect correlation between SUVmax and the time passed between the vaccination and the PET CT (Pearson Correlation r = −0.54, p = 0.005). There was no significant difference (p = 0.19) in the SUVmax value in patients receiving Moderna mRNA-1273 vaccine vs. BNT162b2 mRNA Pfizer vaccine. (4) Conclusions: Lymph node enlargement is commonly seen in patients post-vaccination for COVID-19 and must be differentiated from disease progression. The data from our study strongly suggests that the minimum interval of time between an mRNA vaccine and a PET-CT should be more than six weeks.

show abstract

Sentinel Lymph Node Biopsy after Neoadjuvant Treatment for Breast Cancer. The Validation Protocol

Cited by 2 publications

References 0 publications

Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Axillary Conversion after Neoadjuvant Chemotherapy—A Single-Tertiary Centre Experience and Review of the Literature

Feasibility of Sentinel Lymph Node Biopsy in Breast Cancer Patients with Axillary Conversion after Neoadjuvant Chemotherapy—A Single-Tertiary Centre Experience and Review of the Literature

Understanding COVID Vaccination and Its Implication in Cancer Patients’ Imaging of Lymph Nodes by PET-CT

Contact Info

Product

Resources

About